201 related articles for article (PubMed ID: 2189835)
21. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients.
Kan WC; Chien CC; Wu CC; Su SB; Hwang JC; Wang HY
Nephrol Dial Transplant; 2010 May; 25(5):1604-8. PubMed ID: 19948879
[TBL] [Abstract][Full Text] [Related]
22. The use of intravenous and intraperitoneal desferrioxamine in aluminium osteomalacia.
O'Brien AA; McParland C; Keogh JA
Nephrol Dial Transplant; 1987; 2(2):117-9. PubMed ID: 3112649
[TBL] [Abstract][Full Text] [Related]
23. Periosteal new bone in patients on intermittent haemodialysis: an early indicator of aluminium-induced osteomalacia?
Chambers SE; Winney RJ
Clin Radiol; 1985 Mar; 36(2):163-8. PubMed ID: 4064494
[TBL] [Abstract][Full Text] [Related]
24. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME
Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
[TBL] [Abstract][Full Text] [Related]
25. Ultrafiltrable aluminium after very low doses of desferrioxamine.
Canteros A; Díaz-Corte C; Fernández-Martín JL; Gago E; Fernández-Merayo C; Cannata J
Nephrol Dial Transplant; 1998 Jun; 13(6):1538-42. PubMed ID: 9641189
[TBL] [Abstract][Full Text] [Related]
26. Plasma aluminium levels in patients on maintenance haemodialysis fall when oral aluminium hydroxide is withdrawn.
Wallace MR; Pybus J
N Z Med J; 1983 Oct; 96(742):793-5. PubMed ID: 6578451
[TBL] [Abstract][Full Text] [Related]
27. [Aluminum poisoning caused by the phosphate binder in a non-dialysed child with chronic renal insufficiency].
Feldmann B; Färber D; Pontz BF
Radiologe; 1992 Jul; 32(7):327-32. PubMed ID: 1509030
[TBL] [Abstract][Full Text] [Related]
28. Bone disease in long-term hemodialysis patients with low dialysate aluminium.
Grekas DM; Ellis HA; Ward MK; Martin AM; Parkinson I; Kerr DN
Uremia Invest; 1984; 8(1):9-15. PubMed ID: 6437038
[TBL] [Abstract][Full Text] [Related]
29. Treatment of dialysis osteomalacia with desferrioxamine.
Brown DJ; Dawborn JK; Ham KN; Xipell JM
Lancet; 1982 Aug; 2(8294):343-5. PubMed ID: 6124756
[TBL] [Abstract][Full Text] [Related]
30. Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine.
Mudde AH; Roodvoets AP; Van Groningen K
Neth J Med; 1985; 28(1):6-11. PubMed ID: 3974771
[No Abstract] [Full Text] [Related]
31. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients.
Sawyer N; Noonan K; Altmann P; Marsh F; Cunningham J
Nephrol Dial Transplant; 1989; 4(2):105-9. PubMed ID: 2496350
[TBL] [Abstract][Full Text] [Related]
32. The effect of oral aluminium therapy on plasma aluminium levels in patients with chronic renal failure in an area with low water aluminium.
Fleming LW; Stewart Wk; Fell GS; Halls DJ
Clin Nephrol; 1982 May; 17(5):222-7. PubMed ID: 7094439
[TBL] [Abstract][Full Text] [Related]
33. Solitary, spontaneous cervical and large bone fractures in aluminum osteodystrophy.
Sundaram M; Dessner D; Ballal S
Skeletal Radiol; 1991; 20(2):91-4. PubMed ID: 2020868
[TBL] [Abstract][Full Text] [Related]
34. [Spontaneous fracture in a hemodialyzed woman probably associated with the oral intake of aluminium gel (author's transl)].
Fournier G; Gaillard JL; Bourdon R; Drüeke T
Nephrologie; 1981; 2(1):23-6. PubMed ID: 7345373
[TBL] [Abstract][Full Text] [Related]
35. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
von Bonsdorff M; Sipilä R; Pitkänen E
Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
[TBL] [Abstract][Full Text] [Related]
36. [The role of aluminum in the development of osteomalacia in patients on chronic hemodialysis].
Adamiec R; Uzar J
Pol Arch Med Wewn; 1988 Jan; 79(1):3-12. PubMed ID: 3275167
[TBL] [Abstract][Full Text] [Related]
37. [Renal osteodystrophy (3); its treatment in dialysis patients].
Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
[TBL] [Abstract][Full Text] [Related]
38. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
Salusky IB; Foley J; Nelson P; Goodman WG
N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306
[TBL] [Abstract][Full Text] [Related]
39. Do oral aluminium phosphate binders cause accumulation of aluminium to toxic levels?
Pepper R; Campbell N; Yaqoob MM; Roberts NB; Fan SL
BMC Nephrol; 2011 Oct; 12():55. PubMed ID: 21992770
[TBL] [Abstract][Full Text] [Related]
40. [Effect on serum aluminium levels of continued ingestion of aluminium gels by patients with chronic renal insufficiency (author's transl)].
Boukari M; Rottembourg J; Jaudon MC; Clavel JP; Legrain M; Galli A
Nouv Presse Med; 1978 Jan; 7(2):85-8. PubMed ID: 349501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
